AngioDynamics, Inc. (ANGO) Earnings Call Analysis

NASDAQ · Healthcare · Medical Instruments & Supplies

21/25

Growth 5 Margin 4 Expansion 5 Platform 3 Financial 4

latest quarter score

Earnings Reports

21
AngioDynamics (ANGO) Q4 2026: MedTech Share Hits 48%, Underpinning 18% Segment Growth
July 14, 2026
17
AngioDynamics (ANGO) Q3 2026: MedTech Revenue Jumps 19% as Portfolio Shift Accelerates
April 02, 2026
20
AngioDynamics (ANGO) Q2 2026: MedTech Mix Hits 45% of Sales, Accelerating Margin Expansion
January 06, 2026
18
AngioDynamics (ANGO) Q1 2026: MedTech Mix Reaches 47% as Mechanical Thrombectomy Grows 41%
October 02, 2025
21
AngioDynamics (ANGO) Q4 2025: MedTech Revenue Jumps 22% as Platform Transformation Accelerates
July 17, 2025
18
AngioDynamics (ANGO) Q3 2025: MedTech Surges 22% as AlphaVac Adoption Accelerates
July 06, 2025
AngioDynamics (ANGO) Q1 2025: MedTech Mix Hits 41% of Revenue, Powering Margin Shift
October 03, 2024
AngioDynamics (ANGO) Q4 2024: MedTech Share Doubles to 39% as Platform Expansion Accelerates
July 16, 2024
AngioDynamics (ANGO) Q3 2024: MedTech Revenue Climbs 13% as Portfolio Streamlines for Margin Upside
April 04, 2024
AngioDynamics (ANGO) Q2 2024: $15M Cost Takeout Targets FY27 Profitability Amid Thrombectomy Softness
January 05, 2024
AngioDynamics (ANGO) Q1 2024: MedTech Segment Climbs to 33% of Revenue, Accelerating Margin Shift
October 04, 2023
AngioDynamics (ANGO) Q4 2023: MedTech Segment Climbs to 29% of Revenue, Accelerating Portfolio Shift
July 12, 2023
AngioDynamics (ANGO) Q3 2023: MedTech Grows 17% as AngioVac Weakness Triggers Guidance Cut
March 30, 2023

Browse all companies